Latest & greatest articles for prostate cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on prostate cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on prostate cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for prostate cancer

161. Patient-reported outcomes following enzalutamide or placebo in men with non-metastatic, castration-resistant prostate cancer (PROSPER): a multicentre, randomised, double-blind, phase 3 trial Full Text available with Trip Pro

Patient-reported outcomes following enzalutamide or placebo in men with non-metastatic, castration-resistant prostate cancer (PROSPER): a multicentre, randomised, double-blind, phase 3 trial In the PROSPER trial, enzalutamide significantly improved metastasis-free survival in patients with non-metastatic, castration-resistant prostate cancer. Here, we report the results of patient-reported outcomes of this study.In the randomised, double-blind, placebo-controlled, phase 3 PROSPER trial, done (...) at 254 study sites worldwide, patients aged 18 years or older with non-metastatic, castration-resistant prostate cancer and a prostate-specific antigen doubling time of up to 10 months were randomly assigned (2:1) via an interactive voice web recognition system to receive oral enzalutamide (160 mg per day) or placebo. Randomisation was stratified by prostate-specific antigen doubling time and baseline use of a bone-targeting agent. The primary endpoint was metastasis-free survival, reported elsewhere

2019 EvidenceUpdates

162. A 16-yr Follow-up of the European Randomized study of Screening for Prostate Cancer Full Text available with Trip Pro

A 16-yr Follow-up of the European Randomized study of Screening for Prostate Cancer The European Randomized study of Screening for Prostate Cancer (ERSPC) has previously demonstrated that prostate-specific antigen (PSA) screening decreases prostate cancer (PCa) mortality.To determine whether PSA screening decreases PCa mortality for up to 16yr and to assess results following adjustment for nonparticipation and the number of screening rounds attended.This multicentre population-based randomised (...) significantly reduces PCa mortality, showing larger absolute benefit with longer follow-up and a reduction in excess incidence. Repeated screening may be important to reduce PCa mortality on a population level.In this report, we looked at the outcomes from prostate cancer in a large European population. We found that repeated screening reduces the risk of dying from prostate cancer.Copyright © 2019. Published by Elsevier B.V.

2019 EvidenceUpdates

163. Use of Low-Dose Aspirin and Mortality After Prostate Cancer Diagnosis: A Nationwide Cohort Study. (Abstract)

Use of Low-Dose Aspirin and Mortality After Prostate Cancer Diagnosis: A Nationwide Cohort Study. Recent studies suggest that aspirin use may improve survival in patients with prostate cancer.To assess the association between postdiagnosis use of low-dose aspirin and prostate cancer mortality.Nationwide cohort study.Denmark.Men with incident prostate adenocarcinoma between 2000 and 2011.Nationwide registry data on tumor characteristics, drug use, primary prostate cancer therapy, comorbidity (...) , and socioeconomic parameters. Postdiagnosis use of low-dose aspirin (75 to 150 mg) was defined as 2 or more prescriptions filled within 1 year after prostate cancer diagnosis. Follow-up started 1 year after prostate cancer diagnosis. In secondary analyses, low-dose aspirin use was assessed within exposure periods of 5 or 7.5 years after prostate cancer diagnosis.Of 29 136 patients (median age, 70 years), 7633 died of prostate cancer and 5575 died of other causes during a median follow-up of 4.9 years

2019 Annals of Internal Medicine

164. Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer. Full Text available with Trip Pro

Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer. Darolutamide is a structurally unique androgen-receptor antagonist that is under development for the treatment of prostate cancer. We evaluated the efficacy of darolutamide for delaying metastasis and death in men with nonmetastatic, castration-resistant prostate cancer.We conducted a randomized, double-blind, placebo-controlled, phase 3 trial involving men with nonmetastatic, castration-resistant prostate cancer (...) with a higher incidence of seizures, falls, fractures, cognitive disorder, or hypertension than placebo.Among men with nonmetastatic, castration-resistant prostate cancer, metastasis-free survival was significantly longer with darolutamide than with placebo. The incidence of adverse events was similar for darolutamide and placebo. (Funded by Bayer HealthCare and Orion Pharma; ARAMIS ClinicalTrials.gov number, NCT02200614.).Copyright © 2019 Massachusetts Medical Society.

2019 NEJM Controlled trial quality: predicted high

165. Biodegradable Rectal Spacers for Prostate Cancer Radiotherapy

Biodegradable Rectal Spacers for Prostate Cancer Radiotherapy Recommendation Report 21-5 A Quality Initiative of the Program in Evidence-Based Care (PEBC), Cancer Care Ontario (CCO) Biodegradable Rectal Spacers for Prostate Cancer Radiotherapy P Chung, J Brown, D D‘Souza, W Koll, S Morgan and the biodegradable spacer insertion during radiotherapy for prostate cancer recommendation report group (SPACER RRG) Report Date: January 16, 2019 For information about this document, please contact Dr (...) Spacers for Prostate Cancer Radiotherapy. Toronto (ON): Cancer Care Ontario: 2019, January 16. Program in Evidence- based Care Recommendation Report No.: 21-5. Copyright This report is copyrighted by Cancer Care Ontario; the report and the illustrations herein may not be reproduced without the express written permission of Cancer Care Ontario. Cancer Care Ontario reserves the right at any time, and at its sole discretion, to change or revoke this authorization. Disclaimer Care has been taken

2019 Cancer Care Ontario

166. Axumin for functional imaging of prostate cancer recurrence

Axumin for functional imaging of prostate cancer recurrence Axumin for functional imaging of prostate cancer Axumin for functional imaging of prostate cancer recurrence recurrence Medtech innovation briefing Published: 8 February 2019 nice.org.uk/guidance/mib172 pathways Summary Summary The technology technology described in this briefing is Axumin, a radiopharmaceutical agent. It is intended for use in positron emission tomography (PET) to detect suspected prostate cancer recurrence in people (...) who have elevated prostate-specific antigen levels after primary curative treatment. It is currently the only licensed PET tracer indicated for use in recurrent prostate cancer. The inno innovativ vative aspects e aspects are that it is a prostate cancer-specific PET tracer with a novel mechanism of action based on amino acid transport. Its longer half-life and shorter uptake period may allow use in more people with suspected prostate cancer recurrence compared with other PET tracers. The intended

2019 National Institute for Health and Clinical Excellence - Advice

167. Fluorine- or gallium- prostate-specific membrane antigen (PSMA) positron emission tomography (PET) radiotracers in the investigation of recurrent prostate cancer

Fluorine- or gallium- prostate-specific membrane antigen (PSMA) positron emission tomography (PET) radiotracers in the investigation of recurrent prostate cancer Fluorine- or gallium- prostate-specific membrane antigen positron emission tomography radiotracers - Health Technology Wales > Fluorine- or gallium- prostate-specific membrane antigen positron emission tomography radiotracers Fluorine- or gallium- prostate-specific membrane antigen positron emission tomography radiotracers Topic Status (...) Incomplete Fluorine- or gallium- prostate-specific membrane antigen (PSMA) positron emission tomography (PET) radiotracers in the investigation of recurrent prostate cancer. Outcome of the appraisal The adoption of 68 Ga prostate-specific membrane antigen (PSMA) positron emission tomography (PET) for the diagnosis of recurrent prostate cancer is partially supported by the evidence. The use of 68 Ga PSMA PET provides a high degree of diagnostic accuracy on which to base management decisions as compared

2019 Health Technology Wales

168. Remote monitoring or self-management for surveillance or follow up of prostate cancer

Remote monitoring or self-management for surveillance or follow up of prostate cancer Remote monitoring of prostate cancer - Health Technology Wales > Remote monitoring of prostate cancer Remote monitoring of prostate cancer Topic Status Incomplete Remote monitoring or self-management for surveillance or follow up of prostate cancer. Summary Health Technology Wales researchers searched for evidence on different methods of prostate remote monitoring/self-management. Although a range of evidence

2019 Health Technology Wales

169. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): 10-year results from a randomised, phase 3, (Abstract)

Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): 10-year results from a randomised, phase 3, The optimal duration of androgen suppression for men with locally advanced prostate cancer receiving radiotherapy with curative intent is yet to be defined. Zoledronic acid is effective in preventing androgen suppression-induced bone loss (...) , but its role in preventing castration-sensitive bone metastases in locally advanced prostate cancer is unclear. The RADAR trial assessed whether the addition of 12 months of adjuvant androgen suppression, 18 months of zoledronic acid, or both, can improve outcomes in men with locally advanced prostate cancer who receive 6 months of androgen suppression and prostatic radiotherapy. This report presents 10-year outcomes from this trial.For this randomised, phase 3, 2 × 2 factorial trial, eligible men

2019 EvidenceUpdates

170. Health-related Quality of Life for Abiraterone Plus Prednisone Versus Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer: Results from a Phase II Randomized Trial (Abstract)

Health-related Quality of Life for Abiraterone Plus Prednisone Versus Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer: Results from a Phase II Randomized Trial Abiraterone and enzalutamide are associated with side effects that may impair health-related quality of life (HRQoL).To assess patient-reported HRQoL, depression symptoms, and cognitive function for abiraterone versus enzalutamide.We randomized 202 patients in a phase II study of abiraterone versus (...) enzalutamide for first-line treatment of metastatic castration-resistant prostate cancer (ClinicalTrials.gov: NCT02125357).Patients completed Functional Assessment of Cancer Therapy-Prostate (FACT-P) and Patient Health Questionnaire-9 (PHQ-9) questionnaires, and Montreal Cognitive Assessment (MoCA) cognitive assessments at baseline and on treatment.To compare the change in FACT-P scores over time between treatment arms, we used a mixed model for repeated measures (MMRM). For FACT-P domains where

2019 EvidenceUpdates

171. Safety and Antitumour Activity of ODM-201 (BAY-1841788) in Castration-resistant, CYP17 Inhibitor-naïve Prostate Cancer: Results from Extended Follow-up of the ARADES Trial. Full Text available with Trip Pro

Safety and Antitumour Activity of ODM-201 (BAY-1841788) in Castration-resistant, CYP17 Inhibitor-naïve Prostate Cancer: Results from Extended Follow-up of the ARADES Trial. Patients with castration-resistant prostate cancer (CRPC) had extended responses to the androgen receptor antagonist ODM-201, in phase 1/2 studies.To evaluate the safety and antitumour activity of prolonged ODM-201 treatment in patients with CRPC.The ARADES trial was a multicentre phase 1 (dose escalation) and phase 2 (dose (...) antitumour activity in men with advanced prostate cancer, indicating that ODM-201 may represent a new active treatment for men with CRPC. This extension trial is registered at ClinicalTrials.gov (www.clinicaltrials.gov) under identification number NCT01429064.Copyright © 2017 European Association of Urology. Published by Elsevier B.V. All rights reserved.

2019 European urology focus Controlled trial quality: uncertain

172. Enzalutamide (prostate cancer) - Benefit assessment according to §35a Social Code Book V

Enzalutamide (prostate cancer) - Benefit assessment according to §35a Social Code Book V Extract 1 Translation of the executive summary of the dossier assessment Enzalutamid (Prostatakarzinom) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 26 February 2019). Please note: This document was translated by an external translator and is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding (...) . IQWiG Reports – Commission No. A18-80 Enzalutamide (prostate cancer) – Benefit assessment according to §35a Social Code Book V 1 Extract of dossier assessment A18-80 Version 1.0 Enzalutamide (prostate cancer) 26 February 2019 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Enzalutamide (prostate cancer) – Benefit assessment according to §35a Social Code Book V Commissioning agency: Federal

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

173. Apalutamide (prostate cancer) - Addendum to Commission A19-09

Apalutamide (prostate cancer) - Addendum to Commission A19-09 1 Translation of addendum A19-51 Apalutamid (Prostatakarzinom) – Addendum zum Auftrag A19-09 (Version 1.0; Status: 11 July 2019). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. Addendum 11 July 2019 1.0 Commission: A19-51 Version: Status: IQWiG Reports – Commission No. A19-51 Apalutamide (prostate (...) cancer) – Addendum to Commission A19-09 1 Addendum A19-51 Version 1.0 Apalutamide – Addendum to Commission A19-09 11 July 2019 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Apalutamide (prostate cancer) – Addendum to Commission A19-09 Commissioning agency: Federal Joint Committee Commission awarded on: 12 June 2019 Internal Commission No.: A19-51 Address of publisher: Institut für Qualität und

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

174. Results of Prostate Cancer Screening in a Unique Cohort at 19yr of Follow-up (Abstract)

Results of Prostate Cancer Screening in a Unique Cohort at 19yr of Follow-up We assessed the effect of screening in the European Randomized study of Screening for Prostate Cancer (ERSPC) Rotterdam pilot 1 study cohort with men randomized in 1991-1992. A total of 1134 men were randomized on a 1:1 basis to a screening (S) and control (C) arm after prostate-specific antigen (PSA) testing (PSA ≥10.0ng/ml was excluded from randomization). Further PSA testing was offered to all men in the S-arm (...) with 4-yr intervals starting at age 55yr and screened up to the age of 74yr. Overall, a PSA level of ≥3.0ng/ml triggered biopsy. At time of analysis, 63% of men had died. Overall relative risk of metastatic (M+) disease and prostate cancer (PCa) death was 0.46 (95% confidence interval [CI]: 0.19-1.11) and 0.48 (95% CI: 0.17-1.36), respectively, in favor of screening. This ERSPC Rotterdam pilot 1 study cohort, screened in a period without noteworthy contamination, shows that PSA-based screening could

2019 EvidenceUpdates

175. A Multicentre Evaluation of the Role of the Prostate Health Index (PHI) in Regions with Differing Prevalence of Prostate Cancer: Adjustment of PHI Reference Ranges is Needed for European and Asian Settings (Abstract)

A Multicentre Evaluation of the Role of the Prostate Health Index (PHI) in Regions with Differing Prevalence of Prostate Cancer: Adjustment of PHI Reference Ranges is Needed for European and Asian Settings Asians have a lower incidence of prostate cancer (PC). We compared the performance of the Prostate Health Index (PHI) for 2488 men in different ethnic groups (1688 Asian and 800 European men from 9 sites) with PSA 2-20ng/ml and PHI test and transrectal ultrasound-guided biopsy results (...) ) and for PSA 10-20ng/ml (n=439). PHI is effective in cancer risk stratification for both European and Asian men. However, population-specific PHI reference ranges should be used. PATIENT SUMMARY: The Prostate Health Index (PHI) blood test helps to identify individuals at higher risk of prostate cancer among Asian and European men, and could significantly reduce unnecessary biopsies and overdiagnosis of prostate cancer. Different PHI reference ranges should be used for different ethnic groups.Copyright ©

2019 EvidenceUpdates

176. General medicine: MRI and MRI-targeted biopsy take precedence over systematic biopsy in primary prostate cancer diagnosis

General medicine: MRI and MRI-targeted biopsy take precedence over systematic biopsy in primary prostate cancer diagnosis MRI and MRI-targeted biopsy take precedence over systematic biopsy in primary prostate cancer diagnosis | BMJ Evidence-Based Medicine Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username (...) and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here MRI and MRI-targeted biopsy take precedence over systematic biopsy in primary prostate cancer diagnosis Article Text Commentary General medicine MRI and MRI-targeted biopsy take precedence over systematic biopsy in primary prostate cancer diagnosis Ivo G Schoots 1 , 2 , Olivier Rouvière 3 , 4 Statistics from Altmetric.com Commentary on : Kasivisvanathan V, Rannikko

2019 Evidence-Based Medicine

177. Algorithm for erectile rehabilitation following prostate cancer treatment

Algorithm for erectile rehabilitation following prostate cancer treatment Algorithm for erectile rehabilitation following prostate cancer treatment To view this page ensure that Adobe Flash Player version 10.0.0 or greater is installed. Besides, it's possible to , or you can view flippdf Either scripts and active content are not permitted to run or Adobe Flash Player version 10.0.0 or greater is not installed. Besides, it's possible to , or you can view flippdf

2019 Canadian Urological Association

178. Castration-resistant prostate cancer (CRPC): CUA/CUOG

Castration-resistant prostate cancer (CRPC): CUA/CUOG Castration-resistant prostate cancer (CRPC): CUA/CUOG To view this page ensure that Adobe Flash Player version 10.0.0 or greater is installed. Besides, it's possible to , or you can view flippdf Either scripts and active content are not permitted to run or Adobe Flash Player version 10.0.0 or greater is not installed. Besides, it's possible to , or you can view flippdf

2019 Canadian Urological Association

179. 177Lu-PSMA Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer . Decision Support Document 118.

177Lu-PSMA Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer . Decision Support Document 118. 177Lu-PSMA Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer - Repository of AIHTA GmbH English | Browse - - - 177Lu-PSMA Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer Stanak, M. and Grössmann, N. and Strohmaier, C. (2019): 177Lu-PSMA Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer . Decision Support (...) Document 118. Preview - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. , oder 930kB Abstract The majority of prostate cancer patients have an overexpressed prostate specific membrane antigen (PSMA) that is a target for radionuclide therapy. Our aim was to review the current evidence on clinical effectiveness and safety of 177 Lutetium (Lu) labelled PSMA for metastatic castration-resistant prostate cancer (mCRPC) patients. No controlled trials were found to answer the research

2019 Austrian Institute of Health Technology Assessment

180. Darolutamide for the treatment of patients with nonmetastatic castration-resistant prostate cancer (CRPC). DSD: Horizon Scanning in Oncology 88.

Darolutamide for the treatment of patients with nonmetastatic castration-resistant prostate cancer (CRPC). DSD: Horizon Scanning in Oncology 88. Darolutamide for the treatment of patients with nonmetastatic castration-resistant prostate cancer (CRPC) - Repository of AIHTA GmbH English | Browse - - - Darolutamide for the treatment of patients with nonmetastatic castration-resistant prostate cancer (CRPC) Rothschedl, E. (2019): Darolutamide for the treatment of patients with nonmetastatic (...) castration-resistant prostate cancer (CRPC). DSD: Horizon Scanning in Oncology 88. Preview - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. , oder 1MB Abstract Castration-resistant prostate cancer (CRPC) is a type of prostate cancer that keeps growing even when the testosterone level is reduced to very low. Darolutamide is a nonsteroidal androgen receptor (AR) antagonist with a molecular structure that differs from other AR antagonists. To date, darolutamide is neither approved

2019 Austrian Institute of Health Technology Assessment